Presentation is loading. Please wait.

Presentation is loading. Please wait.

Selection of house dust mite–allergic patients by molecular diagnosis may enhance success of specific immunotherapy  Kuan-Wei Chen, PhD, Petra Zieglmayer,

Published byNeil Harper Modified over 5 years ago

Similar presentations

Presentation on theme: "Selection of house dust mite–allergic patients by molecular diagnosis may enhance success of specific immunotherapy  Kuan-Wei Chen, PhD, Petra Zieglmayer,"— Presentation transcript:

1 Selection of house dust mite–allergic patients by molecular diagnosis may enhance success of specific immunotherapy  Kuan-Wei Chen, PhD, Petra Zieglmayer, MD, René Zieglmayer, Dipl Ing, Patrick Lemell, PhD, Friedrich Horak, MD, Carmen Panaitescu Bunu, MD, PhD, Rudolf Valenta, MD, Susanne Vrtala, PhD  Journal of Allergy and Clinical Immunology  Volume 143, Issue 3, Pages e12 (March 2019) DOI: /j.jaci Copyright © 2018 The Authors Terms and Conditions

2 Fig 1 Development of HDM allergen-specific IgE and IgG reactivities in the study population during AIT. (A) Box plot representation of IgE (left) and IgG (right) levels to Der p 1, Der p 2, and Der p 23 and (B) to Der p 5, Der p 7, and Der p 21 at weeks 0, 23, and 47 (x-axis) as ISUs (y-axis) for the verum (gray) and placebo (white) groups. Fifty percent of the values are within the boxes and nonoutliers between the bars. Horizontal lines within the boxes indicate the median values. Open circles and stars indicate outliers and extreme values, respectively. Statistically significant differences (P < .05) are indicated. Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

3 Fig 1 Development of HDM allergen-specific IgE and IgG reactivities in the study population during AIT. (A) Box plot representation of IgE (left) and IgG (right) levels to Der p 1, Der p 2, and Der p 23 and (B) to Der p 5, Der p 7, and Der p 21 at weeks 0, 23, and 47 (x-axis) as ISUs (y-axis) for the verum (gray) and placebo (white) groups. Fifty percent of the values are within the boxes and nonoutliers between the bars. Horizontal lines within the boxes indicate the median values. Open circles and stars indicate outliers and extreme values, respectively. Statistically significant differences (P < .05) are indicated. Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

4 Fig 2 TNSSs in the verum and placebo groups before and during AIT. Box plot representations of TNSS (areas under the curve [AUC] for the 165-minute chamber session) (y-axes) at weeks 0, 23, and 47 for the verum (gray) and placebo (white) groups (total) and subgroups (group 1: Der p 1 and/or Der p 2 positive, Der p 5, Der p 7, Der p 21, and Der p 23 negative; group 2: Der p 1 and/or Der p 2 positive plus 1-4 of the other allergens). Fifty percent of the values are within the boxes and nonoutliers between the bars. Horizontal lines within the boxes indicate the median values. Open circles indicate outliers. Statistically significant differences between the verum and placebo groups (P < .05) are indicated. Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

5 Fig E1 Scheme of the study. Hundred patients (verum: n = 52; placebo: n = 48) received subcutaneous injections of a mite allergoid or placebo for a period of 47 weeks as indicated in the figure. At weeks 0, 23, and 47, challenge chamber sessions were performed and blood samples were obtained. Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

6 Fig E2 IgE recognition frequencies and intensities of the individual HDM allergens. Shown are the frequencies and intensities (specific IgE levels: blue, ISU = 0.3-1; red, ISUs = 1-15; green, ISUs > 15) of IgE recognition (y-axis) of 15 individual HDM allergens (x-axis) as determined by ImmunoCAP ISAC technology (A) in the study population and (B) for the 57 patients whose data were analyzed in the challenge chamber at week 0 (v: verum; p: placebo). Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

7 Fig E3 Development of HDM allergen-specific IgE and IgG responses during AIT in the study population. Box plot representation of IgE levels (left) and IgG levels (right) to (A) Der f 1, Der f 2, and Der p 4, (B) Der p 10, Der p 11, and Der p 14, and (C) Der p 15, Der p 18, and clone 16, at weeks 0, 23, and 47 (x-axis) as ISUs (y-axis) for the verum (gray) and placebo (white) groups. Fifty percent of the values are within the boxes and nonoutliers between the bars. Lines within the boxes indicate the median values. Open circles and stars indicate outliers and extreme values, respectively. Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

8 Fig E3 Development of HDM allergen-specific IgE and IgG responses during AIT in the study population. Box plot representation of IgE levels (left) and IgG levels (right) to (A) Der f 1, Der f 2, and Der p 4, (B) Der p 10, Der p 11, and Der p 14, and (C) Der p 15, Der p 18, and clone 16, at weeks 0, 23, and 47 (x-axis) as ISUs (y-axis) for the verum (gray) and placebo (white) groups. Fifty percent of the values are within the boxes and nonoutliers between the bars. Lines within the boxes indicate the median values. Open circles and stars indicate outliers and extreme values, respectively. Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

9 Fig E3 Development of HDM allergen-specific IgE and IgG responses during AIT in the study population. Box plot representation of IgE levels (left) and IgG levels (right) to (A) Der f 1, Der f 2, and Der p 4, (B) Der p 10, Der p 11, and Der p 14, and (C) Der p 15, Der p 18, and clone 16, at weeks 0, 23, and 47 (x-axis) as ISUs (y-axis) for the verum (gray) and placebo (white) groups. Fifty percent of the values are within the boxes and nonoutliers between the bars. Lines within the boxes indicate the median values. Open circles and stars indicate outliers and extreme values, respectively. Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

10 Fig E4 TNSSs in the verum and placebo groups before and during AIT. Box plot representations of TNSS recorded at time point 0, after 30 minutes, and then every 15 minutes during the 165-minute chamber session (y-axes) at weeks 0, 23, and 47 for the verum (gray) and placebo (white) groups (total) and subgroups (group 1: Der p 1 and/or Der p 2 positive, Der p 5, Der p 7, Der p 21, and Der p 23 negative; group 2: Der p 1 and/or Der p 2 positive plus 1-4 of the other allergens). Fifty percent of the values are within the boxes and nonoutliers between the bars. Horizontal lines within the boxes indicate the median values. Open circles and stars indicate outliers and extreme values, respectively. Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

11 Fig E5 Skin prick reactivity to HDM extracts before and during AIT (A) in the study population and (B) for the 57 patients whose data were analyzed in the challenge chamber. Box plot representations of the mean wheal diameters of the 10,000 AU/mL concentration (y-axes) at weeks 0, 23, and 47 for the verum (gray) and placebo (white) groups (total) and for subgroups (group 1: Der p 1 and/or Der p 2 positive, Der p 5, Der p 7, Der p 21, and Der p 23 negative; group 2: Der p 1 and/or Der p 2 positive plus 1-4 of the other allergens). Fifty percent of the values are within the boxes and nonoutliers between the bars. Horizontal lines within the boxes indicate the median values. Open circles indicate outliers. Statistically significant differences between the verum and placebo groups (P < .05) are indicated. Journal of Allergy and Clinical Immunology  , e12DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

Download ppt "Selection of house dust mite–allergic patients by molecular diagnosis may enhance success of specific immunotherapy  Kuan-Wei Chen, PhD, Petra Zieglmayer,"

Similar presentations

Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study  Anna.

Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study  Anna.
Volume 11, Pages (September 2016)

Volume 11, Pages (September 2016)
Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines 

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines 
Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies  Marija Geroldinger-Simic, MD, Thomas Zelniker,

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies  Marija Geroldinger-Simic, MD, Thomas Zelniker,
Kuan-Wei Chen, PhD, Katharina Blatt, MSc, Wayne R

Kuan-Wei Chen, PhD, Katharina Blatt, MSc, Wayne R
Corinne A. Keet, MD, MS, Pamela A

Corinne A. Keet, MD, MS, Pamela A
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 
Persistence and evolution of allergen-specific IgE repertoires during subcutaneous specific immunotherapy  Mattias Levin, PhD, Jasmine J. King, BS, Jacob.

Persistence and evolution of allergen-specific IgE repertoires during subcutaneous specific immunotherapy  Mattias Levin, PhD, Jasmine J. King, BS, Jacob.
Prediction of IgE-binding epitopes by means of allergen surface comparison and correlation to cross-reactivity  Fabio Dall'Antonia, PhD, Anna Gieras,

Prediction of IgE-binding epitopes by means of allergen surface comparison and correlation to cross-reactivity  Fabio Dall'Antonia, PhD, Anna Gieras,
Making the Most of In Vitro Tests to Diagnose Food Allergy

Making the Most of In Vitro Tests to Diagnose Food Allergy
Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy  Gabriela Senti, MD, Nicole Graf, PhD, Susanne Haug, MD, Nadine.

Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy  Gabriela Senti, MD, Nicole Graf, PhD, Susanne Haug, MD, Nadine.
Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy  Margarete Focke-Tejkl, PhD, Milena.

Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy  Margarete Focke-Tejkl, PhD, Milena.
Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule  Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,

Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule  Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,
Evaluation of BCG administration as an adjuvant to specific immunotherapy in asthmatic children with mite allergy  Andrea Cohon, MD, L. Karla Arruda,

Evaluation of BCG administration as an adjuvant to specific immunotherapy in asthmatic children with mite allergy  Andrea Cohon, MD, L. Karla Arruda,
Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,
Julie Wang, MD, James H. Godbold, PhD, Hugh A. Sampson, MD 

Julie Wang, MD, James H. Godbold, PhD, Hugh A. Sampson, MD 
Specific IgE and IgG measured by the MeDALL allergen-chip depend on allergen and route of exposure: The EGEA study  Valérie Siroux, PhD, Christian Lupinek,

Specific IgE and IgG measured by the MeDALL allergen-chip depend on allergen and route of exposure: The EGEA study  Valérie Siroux, PhD, Christian Lupinek,
Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis  Friedrich Horak, MD, Kamal D.

Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis  Friedrich Horak, MD, Kamal D.

Similar presentations

Ads by Google